GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Lymphoma, Mantle-Cell
Insel Gruppe AG, University Hospital Bernprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Lymphoma, Mantle-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | BB |
pf-3512676 Ronald Levy | Phase 2 | B |
Bendamustine Ruijin Hospital | Phase 2 | B |
Palbociclib Alliance Foundation Trials, LLC. | Phase 2 | B |
Polatuzumab Vedotin Czech Lymphoma Study Group | Phase 2 | B |
View all 25 →
Same molecule, other indications
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →